Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Cash & Equivalents (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Cash & Equivalents for 7 consecutive years, with $51.7 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 31.28% to $51.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $51.7 million through Dec 2025, down 31.28% year-over-year, with the annual reading at $51.7 million for FY2025, 31.28% down from the prior year.
  • Cash & Equivalents hit $51.7 million in Q4 2025 for Allogene Therapeutics, up from $37.8 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $236.9 million in Q1 2021 to a low of $11.8 million in Q4 2022.
  • Historically, Cash & Equivalents has averaged $92.6 million across 5 years, with a median of $76.9 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: tumbled 89.85% in 2022 and later soared 567.82% in 2023.
  • Year by year, Cash & Equivalents stood at $115.9 million in 2021, then crashed by 89.85% to $11.8 million in 2022, then skyrocketed by 567.82% to $78.5 million in 2023, then dropped by 4.22% to $75.2 million in 2024, then tumbled by 31.28% to $51.7 million in 2025.
  • Business Quant data shows Cash & Equivalents for ALLO at $51.7 million in Q4 2025, $37.8 million in Q3 2025, and $52.3 million in Q2 2025.